Illustration: Sarah Grillo/Axios
Therna Biosciences, which designs RNA-based medicines, raised a $10 million seed, CEO Nazli Azimi tells Axios Pro exclusively.
Why it matters: The startup may raise a Series A in the next 18 months, per Azimi.
